Background
Methods
Study design and setting
Study patients
Measurements
Data analysis
Ethical approval
Results
HCV/HIV- | HCV- | HIV- | P-value* | ||
---|---|---|---|---|---|
Coinfected | Monoinfected | Monoinfected | HCV/HIV | HCV/HI | |
N = 79 | N = 93 | N = 30 | vs HCV | V vs HIV | |
Site (n, %) | <0.001 | <0.001 | |||
HUP | 2 (3%) | 35 (38%) | 0 (0%) | ||
PPMC | 35 (44%) | 20 (22%) | 1 (3%) | ||
PVAMC | 42 (53%) | 38 (41%) | 29 (97%) | ||
Age (Median, IQR) | 55 (43–64) | 57.5 (53.5-61) | 54 (51–60) | 0.04† | NS† |
Sex (n, %) | NS | NS | |||
Male | 68 (86%) | 77 (83%) | 28 (93%) | ||
Female | 11 (14%) | 16 (17%) | 2 (7%) | ||
Race (n, %) | 0.001 | NS | |||
Caucasian | 9 (11%) | 35 (38%) | 5 (17%) | ||
Black | 64 (81%) | 50 (54%) | 24 (80%) | ||
Hispanic | 4 (5%) | 3 (3%) | 0 (0%) | ||
Other | 2 (3%) | 2 (2%) | 1 (3%) | ||
BMI (kg/m2) | 25.0 | 29.2 | 27.2 | <0.001† | 0.05† |
Median (IQR) | (22.5-29.0) | (25.5-33.2) | (25.0-33.2) | ||
Current smoker (n, %) | 29 (37%) | 37 (40%) | 9 (30%) | NS | NS |
HCV Treatment (n, %) | 0.01 | N/A | |||
Current | 4 (5%) | 17 (18%) | 0 (0%) | ||
Past | 22 (28%) | 31 (33%) | 0 (0%) | ||
Never | 53 (67%) | 45 (48%) | 30 (100%) | ||
HCV Genotype (n, %) | NS | N/A | |||
1 (A or B) | 70 (89%) | 60 (65%) | 0 (0%) | ||
2 | 1 (1%) | 5 (5%) | 0 (0%) | ||
3 | 1 (1%) | 4 (4%) | 0 (0%) | ||
HCV RNA (IU/mL) | 1.37 | 0.62 | N/A | 0.02† | N/A |
Median in million (IQR) | (0.44-4.63) | (0.03-2.70) | |||
CD4 count (cells/mm3) | 474 | N/A | 480 | N/A | NS† |
Median (IQR) | (358–666) | (295–673) | |||
Antiretroviral
| 67 (85%) | 0 (%) | 26 (87%) | N/A | NS |
therapy (n, %) | |||||
Previous arthritis diagnosis‡ (n, %) | 37 (40%) | 28 (35%) | 8 (27%) | NS | NS |
Analgesic medication use (n, %) | NS | NS | |||
Any | 41 (52%) | 49 (53%) | 20 (67%) | ||
Opiate | 15 (19%) | 15 (16%) | 4 (13%) | ||
Gabapentin | 17 (22%) | 11 (12%) | 8 (27%) | ||
NSAIDs | 21 (27%) | 23 (25%) | 10 (33%) | ||
Tylenol | 10 (13%) | 18 (19%) | 9 (30%) |
HCV/HIV- | HCV- | HIV- | |
---|---|---|---|
Coinfected | Monoinfected | Monoinfected | |
Physical Function Score (Mean(SD)) | 2.4 (2.0) | 2.6 (1.5) | 3.3 (2.1) |
Pain (Mean(SD)) | 6.5 (2.7) | 5.6 (2.7) | 6.2 (3.2) |
Patient Global (Mean(SD)) | 3.9 (3.3) | 4.4 (2.4) | 4.9 (1.7) |
RAPID3 (Mean(SD)) | 12.8 (6.3) | 12.6 (4.9) | 14.3 (5.6) |
Emotional Score*(Mean(SD)) | 4.2 (2.7) | 3.7 (2.4) | 3.7 (2.3) |
Total Symptoms (Mean(SD))** | 18.6 (10.4) | 17.6 (9.8) | 14.2 (10.8) |
Depression, n (%) | 28 (64%) | 33 (50%) | 12 (80%) |
Anxiety, n (%) | 34 (77%) | 34 (51%) | 10 (67%) |
Sleep Disturbance, n (%) | 32 (73%) | 41 (62%) | 10 (67%) |
Dry Eyes, n (%) | 6 (14%) | 19 (29%) | 0 (0%) |
Dry Mouth n (%) | 20 (45%) | 32 (48%) | 3 (20%) |
Numbness/tingling n (%) | 18 (41%) | 18 (27%) | 1 (7%) |
Myalgias, n (%) | 19 (43%) | 17 (26%) | 1 (7%) |
Morning Stiffness, n (%) | 29 (66%) | 44 (67%) | 8 (53%) |
Fatigue Scale (Mean(SD)) | 4.53 (3.68) | 4.73 (3.44) | 3.97 (3.82) |
≥20 Symptoms Reported | 42 (45%) | 43 (54%) | 7 (23%) |
HCV | HIV | |||
---|---|---|---|---|
Univariable models (Unadjusted) | Multivariable model | Univariable models (Unadjusted) | Final model | |
OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
Co-infection | 0.51 (0.27-0.97) | 0.49 (0.23-1.05) | 1.26 (0.54-2.92) | |
Age (cont) | 1.01 (0.96-1.06) | 0.97 (0.91-1.03) | ||
Female Sex* | 0.95 (0.41-2.23) | 1.41 (0.43-4.63) | ||
Current Smoker | 3.50 (1.71-7.18) | 5.02 (2.15-11.74) | 5.43 (2.18-13.52) | 6.07 (2.30-16.00) |
Obesity (BMI > 30) | 1.85 (0.90-3.79) | 1.29 (0.57-2.92) | 1.70 (0.68-4.29) | |
Previous Diagnosis of Arthritis† | 4.47 (2.11-9.48) | 4.25 (1.84-9.81) | 4,74 (1.90-11.81) | 5.36 (2.01-14.25) |